Clinical Trials Logo

Clinical Trial Summary

The primary safety objective of the study is to assess the safety and tolerability of garetosmab in Japanese male and female adult patients with FOP. The primary efficacy objective of the study is to assess the effect of garetosmab on Heterotopic ossification (HO) in Japanese adult patients with FOP, as determined by the number of new heterotopic bone lesions identified by computed tomography (CT).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04577820
Study type Interventional
Source Regeneron Pharmaceuticals
Contact
Status Withdrawn
Phase Phase 3
Start date October 13, 2021
Completion date October 8, 2022